Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta

Osteoporosis International

Volumn 23, Issue 3, 2012, Pages 1141-1150

  Bargman, R ^a,d   Posham, R ^b   Boskey, A L ^b   Dicarlo, E ^b   Raggio, C ^b   Pleshko, N ^b,c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Alendronate; Mouse; oim oim; Osteogenesis imperfecta; RANK Fc; RANK RANKL

Indexed keywords

ALENDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BODY WEIGHT; BONE; BONE DENSITY; BONE RADIOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DRUG MECHANISM; FEMUR; FRACTURE REDUCTION; GENOTYPE; HISTOPATHOLOGY; INCIDENCE; INFANCY; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THICKNESS; TRABECULAR BONE;

EID: 84857443355     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1742-7     Document Type: Article

References (46)

1. F Rauch FH Glorieux 2004 Osteogenesis imperfecta Lancet 363 1377 1385 15110498 1:CAS:528:DC%2BD2cXjtl2lsLs%3D 10.1016/S0140-6736(04)16051-0 (Pubitemid 38529880)
2. D Gatti F Antoniazzi R Prizzi V Braga M Rossini L Tato O Viapiana S Adami 2005 Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study J Bone Miner Res 20 758 763 15824848 1:CAS:528:DC%2BD2MXnt1yms7o%3D 10.1359/JBMR.041232 (Pubitemid 40571632)
3. D Gatti O Viapiana I Lippolis V Braga R Prizzi M Rossini S Adami 2005 Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta J Bone Miner Res 20 1323 1326 16007328 1:CAS:528:DC%2BD2MXovV2msrY%3D 10.1359/JBMR.050312 (Pubitemid 41033515)
4. FH Glorieux 2007 Experience with bisphosphonates in osteogenesis imperfecta Pediatrics 119 Suppl 2 S163 S165 17332237 10.1542/peds.2006-2023I (Pubitemid 46397938)
5. AD Letocha HL Cintas JF Troendle JC Reynolds CE Cann EJ Chernoff SC Hill LH Gerber JC Marini 2005 Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement J Bone Miner Res 20 977 986 15883638 1:CAS:528: DC%2BD2MXlsFehtrs%3D 10.1359/JBMR.050109 (Pubitemid 40712822)
6. E Madenci K Yilmaz M Yilmaz Y Coskun 2006 Alendronate treatment in osteogenesis imperfecta J Clin Rheumatol 12 53 56 16601536 10.1097/01.rhu. 0000208490.22492.09 (Pubitemid 44309596)
7. R Sakkers D Kok R Engelbert A van Dongen M Jansen H Pruijs A Verbout D Schweitzer C Uiterwaal 2004 Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study Lancet 363 1427 1431 15121405 1:CAS:528: DC%2BD2cXjs1Wnt70%3D 10.1016/S0140-6736(04)16101-1 see comment (Pubitemid 38586718)
8. A Vallo F Rodriguez-Leyva J Rodriguez Soriano 2006 Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy Acta Paediatr 95 332 339 16497645 10.1080/08035250500434785
9. MS Cheung FH Glorieux 2008 Osteogenesis Imperfecta: update on presentation and management Rev Endocr Metab Disord 9 153 160 18404382 10.1007/s11154-008-9074-4
10. LM Ward F Rauch MP Whyte J D'Astous PE Gates D Grogan EL Lester RE McCall TA Pressly JO Sanders PA Smith RD Steiner E Sullivan G Tyerman DL Smith-Wright N Verbruggen N Heyden A Lombardi FH Glorieux 2011 Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study J Clin Endocrinol Metabol 96 2 355 1:CAS:528:DC%2BC3MXisVOms7o%3D 10.1210/jc.2010-0636
11. SL Teitelbaum 2007 Osteoclasts: what do they do and how do they do it? Am J Pathol 170 427 435 17255310 1:CAS:528:DC%2BD2sXitlOls74%3D 10.2353/ajpath.2007.060834 (Pubitemid 47339379)
12. HG Bone MA Bolognese CK Yuen DL Kendler H Wang Y Liu J San Martin 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 18381571 1:CAS:528: DC%2BD1cXntFamtrg%3D 10.1210/jc.2007-2814 (Pubitemid 351831529)
13. JP Brown RL Prince C Deal RR Recker DP Kiel LH de Gregorio P Hadji LC Hofbauer JM Alvaro-Gracia H Wang M Austin RB Wagman R Newmark C Libanati J San Martin HG Bone 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 18767928 1:CAS:528:DC%2BD1MXht1yrtbc%3D 10.1359/jbmr.0809010
14. PJNH Kostenuik J McCabe K Warmington C Kurahara N Sun C Chen L Li RC Cattley G Van S Scully R Elliott M Grisanti S Morony HL Tan F Asuncion X Li MS Ominsky M Stolina D Dwyer WC Dougall N Hawkins WJ Boyle WS Simonet JK Sullivan 2009 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (human/murine) RANKL J Bone Miner Res 24 182 195 19016581 1:CAS:528: DC%2BD1MXitlWktro%3D 10.1359/jbmr.081112
15. AP Armstrong RE Miller JC Jones J Zhang ET Keller WC Dougall 2008 RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes Prostate 68 92 104 18008334 1:CAS:528:DC%2BD1cXhs1yktro%3D 10.1002/pros.20678
16. JR Canon M Roudier R Bryant S Morony M Stolina PJ Kostenuik WC Dougall 2008 Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis Clin Exp Metastasis 25 119 129 18064531 1:CAS:528:DC%2BD1cXmtFyhtbs%3D 10.1007/s10585-007-9127-1
17. LM Childs EP Paschalis L Xing WC Dougall D Anderson AL Boskey JE Puzas RN Rosier RJ O'Keefe BF Boyce EM Schwarz 2002 In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis J Bone Miner Res 17 192 199 11811549 1:CAS:528:DC%2BD38XhtVymtbg%3D 10.1359/jbmr.2002.17.2.192 (Pubitemid 34087651)
18. D Delos X Yang BF Ricciardi ER Myers MP Bostrom NP Camacho 2008 The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta J Orthop Res 26 153 164 17729310 1:CAS:528:DC%2BD1cXitFSgsrw%3D 10.1002/jor.20469 (Pubitemid 351220133)
19. Q Jin JA Cirelli CH Park JV Sugai M Taba Jr PJ Kostenuik WV Giannobile 2007 RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis J Periodontol 78 1300 1308 17608585 10.1902/jop.2007.070073
20. HK Kim S Morgan-Bagley P Kostenuik 2006 RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis J Bone Miner Res 21 1946 1954 17002576 1:CAS:528:DC%2BD28XhtlCku7rF 10.1359/jbmr.060905 (Pubitemid 44851571)
21. RE Miller D Branstetter A Armstrong B Kennedy J Jones L Cowan J Bussiere WC Dougall 2007 Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection J Immunol 179 266 274 17579046 1:CAS:528: DC%2BD2sXmsF2htb4%3D (Pubitemid 46986542)
22. MS Ominsky PJ Kostenuik P Cranmer SY Smith JE Atkinson 2007 The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys Osteoporos Int 18 1073 1082 17384898 1:CAS:528:DC%2BD2sXntVOlsrk%3D 10.1007/s00198-007-0363-7 (Pubitemid 47020009)
23. MS Ominsky X Li FJ Asuncion M Barrero KS Warmington D Dwyer M Stolina Z Geng M Grisanti HL Tan T Corbin J McCabe WS Simonet HZ Ke PJ Kostenuik 2008 RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats J Bone Miner Res 23 672 682 18433301 1:CAS:528:DC%2BD1cXmtFyrsbw%3D 10.1359/jbmr.080109 (Pubitemid 351575021)
24. J Padagas M Colloton V Shalhoub P Kostenuik S Morony L Munyakazi M Guo D Gianneschi E Shatzen Z Geng HL Tan C Dunstan D Lacey D Martin 2006 The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism Calcif Tissue Int 78 35 44 16362459 1:CAS:528: DC%2BD28XkvFKquw%3D%3D 10.1007/s00223-005-0161-1 (Pubitemid 43107290)
25. N Saidenberg-Kermanac'h A Corrado D Lemeiter MC deVernejoul MC Boissier ME Cohen-Solal 2004 TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis Bone 35 1200 1207 15542046 10.1016/j.bone.2004.07.004 (Pubitemid 39487367)
26. M Stolina S Adamu M Ominsky D Dwyer F Asuncion Z Geng S Middleton H Brown J Pretorius G Schett B Bolon U Feige D Zack PJ Kostenuik 2005 RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis J Bone Miner Res 20 1756 1765 16160733 1:CAS:528:DC%2BD2MXhtFGrtLnP 10.1359/JBMR.050601 (Pubitemid 41361876)
27. J Zwerina S Hayer M Tohidast-Akrad H Bergmeister K Redlich U Feige C Dunstan G Kollias G Steiner J Smolen G Schett 2004 Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction Arthritis Rheum 50 277 290 14730626 1:CAS:528:DC%2BD2cXht1Kqsrs%3D 10.1002/art.11487 (Pubitemid 38084313)
28. SD Chipman HO Sweet DJ McBride Jr MT Davisson SC Marks Jr AR Shuldiner RJ Wenstrup DW Rowe JR Shapiro 1993 Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta Proc Natl Acad Sci U S A 90 1701 1705 8446583 1:CAS:528:DyaK3sXhs1KlsL0%3D 10.1073/pnas.90.5.1701 (Pubitemid 23069924)
29. D King D Jarjoura HA McEwen MJ Askew 2005 Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta J Bone Miner Res 20 987 993 15883639 1:CAS:528:DC%2BD2MXlsFehtrg%3D 10.1359/JBMR.050108 (Pubitemid 40712823)
30. NP Camacho CL Raggio SB Doty L Root V Zraick WA Ilg TR Toledano AL Boskey 2001 A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta Calcif Tissue Int 69 94 101 11683430 1:CAS:528:DC%2BD3MXmvVOqsro%3D 10.1007/s002230010045 (Pubitemid 32762911)
31. KD Evans ST Lau AM Oberbauer RB Martin 2003 Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta Bone 32 268 274 12667554 10.1016/S8756-3282(02)00974-2 (Pubitemid 36349530)
32. EA McCarthy CL Raggio MD Hossack EA Miller S Jain AL Boskey NP Camacho 2002 Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model Pediatr Res 52 660 670 12409511 1:CAS:528:DC%2BD38XnvFWrtLw%3D (Pubitemid 35286033)
33. R Bargman A Huang A Boskey C Raggio N Pleshko 2010 RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta Connect Tissue Res 51 123 131 20053133 1:CAS:528:DC%2BC3cXivVSjs7w%3D 10.3109/03008200903108472
34. Bargman R, Boskey A, DiCarlo E, Posham R, Raggio C, Verdelis K, Pleshko N (2009) Osteopetrosis-like changes after treatment with high and low dose OPG-Fc in the diaphyseal regions of infant mice. The Endocrine Society's 91st Annual Meeting Abstract. pp. P2-196
35. BM Misof P Roschger T Baldini CL Raggio V Zraick L Root AL Boskey K Klaushofer P Fratzl NP Camacho 2005 Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse Bone 36 150 158 15664013 1:CAS:528:DC%2BD2MXkvVerug%3D%3D 10.1016/j.bone.2004.10.006 (Pubitemid 40128283)
36. Bouxsein Ml Fau - Boyd SK, Boyd Sk Fau - Christiansen BA, Christiansen Ba Fau - Guldberg RE, Guldberg Re Fau - Jepsen KJ, Jepsen Kj Fau - Muller R, Muller R Guidelines for assessment of bone microstructure in rodents using micro-computed tomography
37. L Filgueira 2004 Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols J Histochem Cytochem 52 411 414 14966208 1:CAS:528: DC%2BD2cXhslOgtbY%3D 10.1177/002215540405200312 (Pubitemid 38229106)
38. MS Ominsky M Stolina X Li TJ Corbin FJ Asuncion M Barrero QT Niu D Dwyer S Adamu KS Warmington M Grisanti HL Tan HZ Ke WS Simonet PJ Kostenuik 2009 One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength J Bone Miner Res 24 1234 1246 19257823 1:CAS:528:DC%2BD1MXosFCkt7w%3D 10.1359/jbmr.090215
39. JA Gasser P Ingold A Venturiere V Shen JR Green 2008 Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat J Bone Miner Res 23 544 551 18072878 1:CAS:528: DC%2BD1cXltFyhsbg%3D 10.1359/jbmr.071207 (Pubitemid 351501895)
40. RR Recker PD Delmas J Halse IR Reid S Boonen PA Garcia-Hernandez J Supronik EM Lewiecki L Ochoa P Miller H Hu P Mesenbrink F Hartl J Gasser EF Eriksen 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16 17892374 1:CAS:528:DC%2BD1cXhtVCmt7c%3D 10.1359/jbmr.070906
41. S Blouin MF Moreau MF Basle D Chappard 2006 Relations between radiograph texture analysis and microcomputed tomography in two rat models of bone metastases Cells Tissues Organs 182 182 192 16914920 1:STN:280: DC%2BD28vptVWqtg%3D%3D 10.1159/000093967 (Pubitemid 44253221)
42. Kimmel Db Fau - Jee WS, Jee WS A quantitative histologic analysis of the growing long bone metaphysis
43. JD Veldhuis JN Roemmich EJ Richmond AD Rogol JC Lovejoy M Sheffield-Moore N Mauras CY Bowers 2005 Endocrine control of body composition in infancy, childhood, and puberty Endocr Rev 26 114 146 15689575 1:CAS:528: DC%2BD2MXitFykt70%3D 10.1210/er.2003-0038 (Pubitemid 40209389)
44. F Rauch C Munns C Land FH Glorieux 2006 Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation J Clin Endocrinol Metab 91 1268 1274 16434452 1:CAS:528:DC%2BD28XjvFOks7Y%3D 10.1210/jc.2005-2413
45. PD Papapetrou 2009 Bisphosphonate-associated adverse events Hormones (Athens) 8 96 110
46. B Jonsson O Strom JA Eisman A Papaioannou ES Siris A Tosteson JA Kanis 2010 Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Osteoporos Int 22 3 967 982 20936401 10.1007/s00198-010-1424-x